Danimer Scientific, Inc. (NYSE:DNMR) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET
Company Participants
James Palczynski - IR
Stephen Croskrey - CEO & Chairman
Michael Hajost - CFO
Conference Call Participants
Kevin Estok - Jefferies
Thomas Boyes - TD Cowen
Jonathan Tanwanteng - CJS Securities
Charles Neivert - Piper Sandler & Co.
Operator
Greetings. Welcome to the Danimer Scientific 2023 First Quarter Earnings Call. [Operator Instructions]. This call is being recorded on Wednesday, May 10 2023. I would now like to turn the presentation over to Mr. James Palczynski, the Company's Investor Relations representative.
James Palczynski
Thank you, operator, and good afternoon to everyone, and thank you for joining us today for Danimer Scientific's 2023 First Quarter Earnings Call. Leading the call today is Steve Croskrey, Chairman and Chief Executive Officer; and Mike Hajost, Chief Financial Officer. I'd like to note that there is a slide deck that accompanies today's discussion, which is available on the Investor Relations section of our website at danimerscientific.com. I'll call your attention to the company's safe harbor language, which is published in our SEC filings and on Slide 2 of the presentation I just referenced.
On today's call, we may discuss forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 as amended. Forward-looking statements include, among other things, statements regarding future results of operations, including margins, profitability, capacity, production, customer programs and market demand levels. Actual results could differ materially from what is expressed or implied in our forward-looking statements. The company assumes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
Today's presentation also includes references to non-GAAP financial measures within the meaning of SEC Regulation G. We believe these non-GAAP measures have analytical value but note that they should be taken as an additional measure of performance to GAAP results. We have provided reconciliations for non-GAAP financial measures to the most comparable GAAP financial measures in our earnings release and our presentation.
Thank you. And it's now my pleasure to turn the call over to Steve Croskrey, Chairman and Chief Executive Officer of Danimer Scientific.
Stephen Croskrey
Thank you, James. Good afternoon, and thank you for joining us to talk about our progress thus far in 2023. When we reported our 2022 year-end results, we were just a few days shy of completing our first quarter, and as you might anticipate, our quarterly results are in line with our expectations. They show the pressure of a timing shift in top line revenue, which impacted gross profitability, but that temporary situation is now behind us.